Oncology

Latest News

Dordaviprone is indicated for recurrent H3 K27M-mutant diffuse midline glioma, an ultra-rare, aggressive brain tumor primarily affecting children. | Image credit: wladimir1804 - stock.adobe.com
FDA Approves Dordaviprone as First and Only Treatment for Aggressive Form of Glioma

August 6th 2025

Dordaviprone (Modeyso) is now approved to treat recurrent H3 K27M-mutant diffuse midline glioma, an ultra-rare, aggressive brain tumor primarily affecting children.

Gen Li, PhD, MBA, president and founder of Phesi
Real-World Data, Digital Patient Profiles Are Revolutionizing Trial Design, Patient Recruitment: Gen Li, PhD, MBA

August 4th 2025

Value-based care. | Image Credit: irissca - stock.adobe.com
Legal Navigation Services Key to Addressing Disparities in Cancer Care

July 31st 2025

Radiotherapy can work synergistically with immunotherapy by reprogramming the tumor microenvironment. | Image credit: Crystallight-stock.adobe.com
Brain Radiotherapy Plus ICIs Boost Survival in SCLC With Brain Metastases

July 30th 2025

As SCLC continues to pose a therapeutic challenge due to rapid progression and early metastasis, the convergence of immunotherapy and precision radiation holds promise to extend survival and improve outcomes. | Image credit: mi_viri - stock.adobe.com
Chemoimmunotherapy Shows Promise for Limited-Stage SCLC in Real-World Study

July 29th 2025

Join this expert panel to discuss precision medicine in NSCLC, current immunotherapies, and more.

Watch the series now!

Join a panel of leaders as they discuss treatment for patients diagnosed with metastatic NSCLC without driver mutations
Continuing Medical Education
View All
August 11th 2025

The Economics of Transthyretin-Mediated Amyloidosis: Balancing Equity and Access in Resource Allocation

1 Credit / Cardiology, Neurology
August 11th 2025

Advancing Immunotherapy in Endometrial Cancer: A Managed Care Perspective on Personalized Care

1.5 Credits / Gynecologic Cancer, Health Equity, Diversity & Inclusion, Oncology, Women's Health

More News

Site Logo
November 12th 2015

Smoking Rates Declining but Disparities Evident: CDC Report

Surabhi Dangi-Garimella, PhD
According to the CDC, while smoking rates are seeing a steady decline, rates for uninsured and adults on Medicaid are more than twice those for adults with private health insurance.
Site Logo
November 12th 2015

Learning From Your Daughters About Cancer Prevention

Surabhi Dangi-Garimella, PhD
A study in The European Journal of Public Health finds conversation on preventive vaccination against HPV can motivate participation in preventive screening for cervical cancer.
Site Logo
November 11th 2015

Oral Contraceptives Can Improve Outcomes in Ovarian Cancer

Surabhi Dangi-Garimella, PhD
A retrospective study conducted at the Mayo Clinic found improved OS and PFS in ovarian cancer patients with a history of oral contraceptive use.
Site Logo
November 11th 2015

Narrow Network and Insolvent Exchange Plan Leaves Cancer Patients Scampering for Options

Surabhi Dangi-Garimella, PhD
A forced closing of Health Republic Insurance of New York has left many in need of immediate coverage.
Dr Crystal S. Denlinger Discusses Potential Cardiotoxicity Concerns for Cancer Survivors
November 10th 2015

Dr Crystal S. Denlinger Discusses Potential Cardiotoxicity Concerns for Cancer Survivors

Historically cancer survivorship programs have not emphasized cardiac follow-up and there is not a lot of long-term data on cardiac toxicity in patients who received certain drugs, but that is changing as patients live longer and fuller lives after treatment, explained Crystal S. Denlinger, MD, from the Fox Chase Cancer Center in Philadelphia.
Site Logo
November 10th 2015

Cobimetinib/Vemurafenib Receives FDA Approval in Advanced Melanoma

AJMC Staff
The approval comes after a priority review of the combination that blocks activity of 2 MAPK proteins: BRAF and MEK.
Site Logo
November 10th 2015

A Cancer Prevention Trial Identifies Predictive Biomarker in Oral Cancer Development

Surabhi Dangi-Garimella, PhD
Published in JAMA Oncology, the trial found an association between loss of heterozygosity and cancer-free survival in patients who had been diagnosed with oral premalignant lesions.
Site Logo
November 9th 2015

Medi-Cal Cancer Patients Perform Worse Than Those on Other Insurance, UC Davis Study

Surabhi Dangi-Garimella, PhD
Heterogeneity in quality of care and cancer patient survival based on insurance coverage are the highlight of a report by researchers at the Institute for Population Health Improvement at the University of California Davis.
Site Logo
November 9th 2015

Exceptional Response in Brain Tumor Patient Instills Confidence in Personalized Medicine

Surabhi Dangi-Garimella, PhD
Treatment of a recurrent brain tumor harboring a BRAF mutation with an inhibitor approved for melanoma resulted in dramatic tumor shrinkage.
Site Logo
November 8th 2015

Advancing the Wave of Democratization of Cancer Care

Emmanuel F. Petricoin III, PhD
Democratizing the complex field of cancer care is not easy. We are providing patients with key information that their own cancer is unique and needs to be treated as such, but there is a great deal of work to be done in putting that knowledge to work.
This Week in Managed Care: November 7, 2015
November 7th 2015

This Week in Managed Care: November 7, 2015

This week in managed care Kentucky elected a new governor who could bring big changes to the state's Medicaid program, researchers reported that costs of dementia in the last 5 years of life surpass even cancer, and the latest Hospital Safety Score report was released.
Site Logo
November 6th 2015

Plavix Does Not Increase the Risk of Cancer

Surabhi Dangi-Garimella, PhD
The FDA's meta-analyses, following results of the DAPT trial in 2014, have found no association between treatment with the blood thinner clopidogrel (Plavix) and increased incidence of, or death due to, cancer.
Site Logo
November 6th 2015

5 Things to Know About Value in Healthcare

Surabhi Dangi-Garimella, PhD
From CMS to private health plans, professional healthcare organizations to patients and advocacy groups, the discussion nowadays seems to end up with value.
Linda House on Considering How a Patient's Needs May Change
November 5th 2015

Linda House on Considering How a Patient's Needs May Change

As patients with cancer live longer and the disease becomes a chronic disease for many, it becomes important for providers to understand how the needs of the patient change from being newly diagnosed to active therapy to long-term therapy, explained Linda House, president of the Cancer Support Community.
Site Logo
November 5th 2015

Study Yields Path to Smart Treatment in Prostate Cancer

Surabhi Dangi-Garimella, PhD
A blood test that can detect mutations in the androgen receptor can predict response to abiraterone in prostate cancer.
Site Logo
November 5th 2015

Optimizing Hashtags to Organize Health Information on Twitter

Surabhi Dangi-Garimella, PhD
New research, published in JAMA Oncology, presents evidence of how the use of disease-specific hashtags on Twitter can help those with common interests collectively share information.
Site Logo
November 4th 2015

Prostate Cancer Study Rekindles Price Transparency Debate

Surabhi Dangi-Garimella, PhD
Published in the journal Cancer, the study evaluated the short-term and long-term costs of treating patients with low-risk prostate cancer across the entire care spectrum.
Site Logo
November 4th 2015

Contraceptive Procedure Can Reduce the Risk of Specific Subtypes of Ovarian Cancer

Surabhi Dangi-Garimella, PhD
According to a study published in The International Journal of Cancer, tubal ligation can reduce the risk of serous, endometrioid, and clear cell ovarian carcinoma.
Site Logo
November 4th 2015

Kentucky's New Governor Could Change the Terms of Medicaid Expansion

Mary K. Caffrey
Departing Governor Steve Beshear's full embrace of the Affordable Care Act brought health coverage to 500,000 people in Kentucky, including many who had never had insurance. Preventive services increased by more than 100%.
Site Logo
November 3rd 2015

Antihypertensive Drug Could Be an Inexpensive Anticancer Agent

Surabhi Dangi-Garimella, PhD
A new research study published in the Journal of Dermatology has found that propranolol, a commonly used antihypertensive agent, could substantially reduce proliferation of angiosarcoma.
Site Logo
November 3rd 2015

ASCO Confirms Support for the President's Nominee for FDA Commissioner

AJMC Staff
Fifty organizations, including the American Society of Clinical Oncology, have expressed their confidence in Robert Califf, MD, to lead the FDA.
Site Logo
November 3rd 2015

Impact of ASCO Results Hold: Pembrolizumab Granted Breakthrough in Advanced CRC

Surabhi Dangi-Garimella, PhD
After melanoma and non-small cell lung cancer, the FDA has granted Breakthrough Therapy status to pembrolizumab in advanced colorectal cancer patients with mismatched repair deficiency.
This Week in Managed Care: October 31, 2015
October 31st 2015

This Week in Managed Care: October 31, 2015

This week in managed care, The American Journal of Managed Care celebrated 20 years and presented its first Emerging Leader award, plus confusion reigns after study links processed meats to cancer and death rates on the decline.
Site Logo
October 30th 2015

UnitedHealthcare to Expand Existing Bundled Payment Model in Oncology

Surabhi Dangi-Garimella, PhD
With the expansion, UnitedHealthcare will bring 5 more oncology practices on board to participate in its bundled program, which will grow the program to 650 oncologists across 7 states.
Dr Lee Newcomer on Value Calculators and New Immuno-Oncology Agents
October 30th 2015

Dr Lee Newcomer on Value Calculators and New Immuno-Oncology Agents

Although there have been a number of new value calculators created recently, UnitedHealthcare does not plan to use any just now. Instead, it will continue covering regimens recommended by the National Comprehensive Cancer Network and in a few years the company will use data from its prior authorization tool to analyze performance of regimens, explained Lee Newcomer, MD, MHA, senior vice president, Oncology, Genetics and Women's Health, UnitedHealthcare.
Ted Okon Outlines the Purpose of COA's Payer Exchange Summit
October 30th 2015

Ted Okon Outlines the Purpose of COA's Payer Exchange Summit

The Community Oncology Alliance (COA) created its Payer Exchange Summit to get payers who are thinking about getting involved in oncology payment reform or want to know what to do exposed to successful pilots, explained Ted Okon, MBA, executive director of COA.
Site Logo
October 30th 2015

Dr Julie M. Vose to Discuss Value, Quality, and Cost in AJMC Tweetchat

On November 3, at 11 a.m. EST, the president of the American Society of Clinical Oncology will host a tweetchat with The American Journal of Managed Care. Get a preview of Dr. Julie Vose's speech at Patient-Centered Oncology Care.
Site Logo
October 29th 2015

Challenges With Transforming Into an Oncology Medical Home

Surabhi Dangi-Garimella, PhD
At the Payer Exchange Summit on Oncology Payment Reform, hosted by the Community Oncology Alliance, Daniel McKellar, MD, who chairs the Commission on Cancer, insisted on meaningful feedback from the community to ensure adequate transformation of practices into a medical home.
Site Logo
October 29th 2015

Medicaid Coverage for Smoking Cessation Improves, but Barriers Remain, CDC Finds

Mary K. Caffrey
More states cover all recommended evidence-based treatments, although many require copayments or put annual limits on care.
How Could Genetic Testing Have the Most Impact?
October 29th 2015

How Could Genetic Testing Have the Most Impact?

<1
...
118119120121122123124125126
...
187>

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

© 2025 MJH Life Sciences® and AJMC®.
All rights reserved.

About
Contact
Editorial Boards
Advertise
Do Not Sell My Information
Terms & Conditions
Privacy Policy
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo